



## Dipole moment studies on $\alpha$ -hydroxy- $\beta$ -lactam derivatives

Aparna Das<sup>\*a</sup> and Bimal Krishna Banik<sup>\*b</sup>

<sup>a</sup>Department of Mathematics and Natural Sciences, College of Sciences and Human Studies, Prince Mohammad Bin Fahd University, Al Khobar 31952, KSA

<sup>b</sup>Department of Mathematics and Natural Sciences, College of Sciences and Human Studies, Deanship of Research, Prince Mohammad Bin Fahd University, Al Khobar 31952, KSA

E-mail: aparnadasam@gmail.com, bimalbanik10@gmail.com, bbanik@pmu.edu.sa

Manuscript received online 09 July 2020, accepted 25 August 2020

In this study, the dipole moment of  $\alpha$ -hydroxy- $\beta$ -lactam derivatives are discussed in detail. Both the hydroxy and acetoxy derivatives of monocyclic *cis* and *trans*  $\beta$ -lactam are considered for this investigation. The influence of the substituted group at N<sub>1</sub> position on the polarity is also investigated. Four quantum mechanical methods (AM1, RM1, PM3 and PM6) are chosen to calculate dipole moment of these molecules. Best of our knowledge, this is the first study on the dipole moment of hydroxy  $\beta$ -lactam derivatives which are related to taxol and taxotere anticancer agents.

Keywords:  $\alpha$ -Hydroxy- $\beta$ -lactam, dipole moment, quantum mechanical methods.

### Introduction

$\beta$ -Lactams are biologically important compounds. They are the core part of important antibiotics such as penicillin derivatives, thienamycins, cephalosporins, monobactams, carbapenem and carbacephem<sup>1,2</sup>. Along with antibiotics application,  $\beta$ -lactams have also other pharmaceutical applications as anti-inflammatory<sup>3</sup>, antifungal<sup>4</sup>, antihepatitis<sup>5</sup>, analgesic properties<sup>6</sup>, antihyperglycemic<sup>7</sup>, LHRH antagonists<sup>8</sup>, cholesterol absorption inhibitors<sup>9</sup>, and anticancer agents<sup>10</sup>. In addition,  $\beta$ -lactams also have received significant attention from medicinal and synthetic chemists because of their importance in organic synthesis as versatile synthetic intermediates and chiral synthons<sup>11</sup>. Several research groups have reported a large variety of  $\beta$ -lactam based synthetic methods<sup>12</sup>. The applications of  $\beta$ -lactams have led to the development of numerous syntheses like indolizidine alkaloids, taxoids, paclitaxel, docetaxel, cytophycins, lankacidins, variety of non-protein amino acids, oligopeptides, peptidomimetics and nitrogen-heterocycles. Among numerous synthetic intermediates, application of  $\beta$ -lactams for taxol (paclitaxel), taxotere (docetaxel) and their analogs<sup>13</sup> have acquired much attention because of the anti-tumor activity of taxol related compounds.  $\alpha$ -Hy-

droxy- $\beta$ -lactam are the intermediates for the semi-synthesis of taxol and its analogs.

Over the past decades, our group have synthesized and disclosed pharmaceutically important  $\alpha$ -hydroxy- $\beta$ -lactam and their derivatives<sup>14</sup>. Besides, we have carried out synthesis and computational studies of different biologically important compounds<sup>15</sup>. In this study, we present quantum mechanical dipole moment calculations of  $\alpha$ -hydroxy- $\beta$ -lactam derivatives. Both the hydroxy (OH) and acetoxy (OAc) derivatives of *cis* and *trans*  $\beta$ -lactam are considered for this investigation. According to our knowledge, this is the first study on the dipole moment calculation of  $\alpha$ -hydroxy- $\beta$ -lactam derivatives. The dipole moment data has shown a consistent trend in all of these  $\beta$ -lactams regardless of their stereochemical distribution.

### Materials and methods

#### $\alpha$ -Acetoxy- $\beta$ -lactams:


The molecular structures and energy minimized structure of the  $\alpha$ -acetoxy- $\beta$ -lactams are shown in Scheme 1. Compound **1** and compound **2** have same molecular formula (identical compounds), they are stereoisomers. Since the stereoisomers has showed remarkable difference in the prop-

erties, we have included both the *cis* and *trans* isomers in this study. Compound **1** is a *cis* isomer and compound **2** is a *trans* isomer. They have a phenyl group linked to N<sub>1</sub> position of the β-lactam ring, oxygen at the C<sub>2</sub> position, an acetoxy group at the C<sub>3</sub> position of the ring and a phenyl group at the C<sub>4</sub> position. To investigate the influence of the substituted group at the N<sub>1</sub> position, other compounds **4** and **5** are also explored. Compounds **4** and **5** have a CO-phenyl group linked to N<sub>1</sub> position of the β-lactam ring instead of phenyl group.


Compounds **4** (*cis*) and compound **5** (*trans*) are stereoisomer.

*α*-Hydroxy-β-lactams:


The molecular structures and energy minimized structure of the α-hydroxy-β-lactams are shown in Scheme 2. α-Hydroxy-β-lactams have a hydroxy group (OH) at the C<sub>3</sub> position of the ring. Compound **5** and compound **6** are stereoisomers. They have a phenyl group linked to N<sub>1</sub> position of the β-lactam ring, oxygen at the C<sub>2</sub> position, and a phenyl



**Scheme 1.** The chemical and optimized structures of the α-acetoxy-β-lactams.



**Scheme 2.** The chemical and optimized structures of the α-hydroxy-β-lactams.



**Scheme 3.** Synthesis of compounds **3** and **4**, i-ii: CAN/H<sub>2</sub>O/CH<sub>3</sub>CN; PhCOCl/TEA.

group at the C<sub>4</sub> position. The other two  $\alpha$ -hydroxy  $\beta$ -lactams **7** and **8** have a CO-phenyl group linked to N<sub>1</sub> position of the  $\beta$ -lactam ring instead of phenyl group and they are stereoisomer.

#### Synthesis of $\alpha$ -hydroxy- $\beta$ -lactams:

Different methods are available for the synthesis of  $\alpha$ -hydroxy  $\beta$ -lactams derivatives<sup>14</sup>. Scheme 3 shows the schematics of the synthesis of compound **3** and **4**<sup>14c-f</sup>.

#### Dipole moment calculation:

In this study all the dipole moment calculations were done using the SPARTAN 18 software package. All the measurements were performed with equilibrium geometry at ground state, using four semi-empirical quantum chemistry methods, Austin Model 1 (AM1), Recife Model 1 (RM1), Parametric Model number 3 (PM3), and Parametric Model number 6 (PM6). All the methods were based on the Neglect of Differential Diatomic Overlap (NDDO) integral approximation. All the structures were drawn in 2D and then converted into their 3D forms using the same software followed by their optimization procedure.

## Results and discussion

The calculated ground-state dipole moment ( $\mu$ ) values in Debye (D) for eight  $\alpha$ -hydroxy- $\beta$ -lactams derivatives are shown in Table 1. The compounds **1**, **3**, **5** and **7** are *cis* in nature and the compounds **2**, **4**, **6** and **8** are *trans*  $\beta$ -lactams.

Compounds	Dipole moment in Debye (D)			
	AM1	RM1	PM3	PM6
<b>1</b>	5.6	5.55	5.64	6.35
<b>2</b>	6.29	6.42	5.32	7.08
<b>3</b>	2.64	2.54	2.4	2.67
<b>4</b>	4.81	4.52	4.33	5.2
<b>5</b>	2.57	2.52	2.19	2.72
<b>6</b>	3.04	3	2.18	3.2
<b>7</b>	1.72	2.06	1.75	1.95
<b>8</b>	2.45	2.44	2.22	2.77

From the calculation it is observed that *trans* compounds has higher dipole moment than *cis* regardless of the sub-

stituent present in the N<sub>1</sub> and C<sub>3</sub> position.

The *trans* compound with an acetoxy (OAc) group at the C<sub>3</sub> position showed more dipole moment than corresponding compounds with hydroxyl (OH) group. Following AM1 calculations, *trans* compounds with OAc at C<sub>3</sub> position and phenyl at N<sub>1</sub> position (compound **2**) showed the highest dipole moment (6.29D), followed by the compound **4** (4.81D) that has OAc at C<sub>3</sub> position and CO-phenyl group at N<sub>1</sub> position. Compounds **6** and **8** showed low dipole moment values 3.04D and 2.45D, because of the presence of the OH group. *Cis* compounds also showed the same trend. The compound with OAc showed higher dipole moment than *cis* compound with CO-phenyl and OH compound. For instance, the compound **7** showed the lowest dipole moment (1.72D). All the four quantum mechanical calculations (AM1, RM1, PM3 and PM6) showed comparable dipole moment values. Surprisingly the dipole moment values of all the compounds from the PM3 calculations were lower compared to data from other methods.

#### Mechanism:

From our dipole moment calculations, it is understood that *trans*- $\alpha$ -hydroxy- $\beta$ -lactams derivatives have higher dipole moment compared to corresponding *cis*- $\alpha$ -hydroxy- $\beta$ -lactams derivatives. The energy minimized 3D structure of the acetoxy stereoisomers showed in *cis* isomers **1**, the oxygen in the ring atom and oxygen in the acetoxy group are two close each other (2.9 Å separation) compared to oxygen atoms in *trans* isomer **2** (5.1 Å) as shown in Fig. 1. Because of this close proximity in *cis* isomers, electronic repulsion takes place and therefore polarity decreases due to overcrowding. Highest dipole moment was expected for compound **4**, but because of close proximity of oxygen atoms in the acetoxy group, oxygen at the C<sub>2</sub> position and oxygen at




Fig. 1. Separation distance of oxygen atoms in stereoisomers.

the N<sub>1</sub> position (3.3 Å and 3.9 Å separation), polarity effects counter balance each other and overall effect resulting in a reduced dipole moment.

#### Conclusions

In this study eight  $\alpha$ -hydroxy- $\beta$ -lactams derivatives are analyzed with four semi-empirical quantum mechanical dipole moment calculations. Dipole moment is observed to be high for *trans* compounds regardless of the group present in the N<sub>1</sub> and C<sub>3</sub> position. All the quantum mechanical calculations followed the same trend. This study is significant and novel, since dipole moment values have played an important role in determining the biological activity of many compounds. But, this type of study has not been investigated with  $\beta$ -lactams that have a wide range of medicinal properties. These results may open a way to design and synthesize more active  $\beta$ -lactam based drugs.

#### Acknowledgements

AD and BKB are grateful to Prince Mohammad Bin Fahd University for encouragement.

#### Supporting materials

All the supporting materials will be available on request.

#### References

1. K. B. Holten and E. M. Onusko, *American Family Physician*, 2000, **62**, 611.
2. G. I. Georg, "The Organic Chemistry of  $\beta$ -Lactams and references cited therein", VCH, New York, 1992.
3. S. K. Srivastava, S. L. Srivastava and S. D. Srivastava, *Indian J. Chem.*, 2000, **39B**, 464.
4. M. O'Driscoll, K. Greenhalgh, A. Young, E. Turos, S. Dickey and D. V. Lim, *Bioorg. Med. Chem.*, 2008, **16**, 7832.
5. M. S. Lall, Y. K. Ramtohl, M. N. James and J. C. Vederas, *J. Org. Chem.*, 2002, **67**, 1536.
6. C. Saturnino, B. Fusco, P. Saturnino, G. De Martino, F. Rocco and J. C. Lancelot, *Biol. Pharm. Bull.*, 2000, **23**, 654.
7. R. K. Goel, M. P. Mahajan and S. K. Kulkarni, *J. Pharm. Pharm. Sci.*, 2004, **7**, 80.
8. C. D. Guillon, G. A. Koppel, M. J. Brownstein, M. O. Chaney, C. F. Ferris, S. F. Lu, K. M. Fabio, M. J. Miller, N. D. Heindel, D. C. Hunden, R. D. G. Cooper, S. W. Kaldox, J. J. Skelton, B. A. Dressman, M. P. Clay, M. I. Steinberg and R. F. Bruns, *Bioorg. Med. Chem.*, 2007, **15**, 2054.
9. (a) D. A. Burnett, M. A. Caplen, H. R. Darris (Jr.), R. E. Burrier and J. W. Clader, *J. Med. Chem.*, 1994, **37**, 1734; (b) J. W. Clader, D. A. Burnett, M. A. Caplen, M. S. Domalski, S. Dugar, W. Vaccaro, R. Sher, M. E. Browne, H. Zhao, R. E. Burrier, B.

- Salisbury and H. R. Davis, *J. Med. Chem.*, 1996, **39**, 3684; (c) J. W. Clader, *J. Med. Chem.*, 2004, **47**, 1; (d) D. A. Burnett, *Curr. Med. Chem.*, 2004, **11**, 1873.
10. (a) I. Banik, F. F. Becker and B. K. Banik, *J. Med. Chem.*, 2003, **46**, 12; (b) B. K. Banik, F. F. Becker and I. Banik, *Bioorg. Med. Chem.*, 2004, **12**, 2523; (c) B. K. Banik, I. Banik and F. F. Becker, *Euro. J. Med. Chem.*, 2009, **45**, 846; (d) B. K. Banik, Ed.  $\beta$ -Lactams: Synthesis, Stereochemistry, Synthons and Biological Evaluation. *Curr. Med. Chem.*, 2004, **12**; (e) B. K. Banik and F. F. Becker, *Mol. Med. Rep.*, 2010, **3**, 315; (f) B. K. Banik, I. Banik and F. F. Becker, *Bioorg. Med. Chem.*, 2005, **13**, 3611; (g) D. Bandyopadhyay, J. Cruz and B. K. Banik, *Tetrahedron Symposium-in-Print*, 2012, **68**, 10686; (i) B. K. Banik, S. Samajdar and F. F. Becker, *Molecular Medicine Reports*, 2010, **3**, 319.
  11. (a) I. Ojima, *Acc. Chem. Res.*, 1995, **28**, 383; (b) B. Alcaide and P. Almendros, *Curr. Med. Chem.*, 2004, **11**, 1921; (c) A. R. Deshmukh, B. M. Bhawal, D. Krishnaswamy, V. V. Govande, B. A. Shinkre and A. Jayanthi, *Curr. Med. Chem.*, 2004, **11**, 1889; (d) C. Palomo, J. M. Aizpurua, I. Ganboa and M. Oiardide, *Curr. Med. Chem.*, 2004, **11**, 1837.
  12. (a) A. K. Bose, C. Mathur, D. R. Wagle, R. Naqvi, M. S. Manhas and Z. U.-Lipkowska, *Heterocycles*, 1995, **39**, 491; (b) B. K. Banik, M. S. Manhas and A. K. Bose, *J. Org. Chem.*, 1993, **58**, 307 and references cited therein; (c) I. Ojima, I. Habus, M. Zhao, G. I. Georg and L. R. Jayasinghe, *J. Org. Chem.*, 1991, **56**, 1681; (d) G. I. Georg, Z. S. Cheruvallath, R. H. Himes, M. R. Mejillano and C. T. Burke, *J. Med. Chem.*, 1992, **35**, 4230; (e) S. Thaisrivongs, D. T. Pals, L. T. Kroll, S. R. Turner and F.-S. Han, *J. Med. Chem.*, 1987, **30**, 976; (f) J. R. Huff, *J. Med. Chem.*, 1991, **34**, 2305; (g) E. Forro and F. Fulop, *Mini-Rev. Org. Chem.*, 2004, **1**, 93; (h) R. Brieva, J. Z. Crich and C. J. Sih, *J. Org. Chem.*, 1993, **58**, 1068; (i) D. M. Spero, S. Kapadia and V. Farina, *Tetrahedron Lett.*, 1995, **36**, 4543.
  13. K. Hattori and H. Yamamoto, *Tetrahedron. Lett.*, 1994, **50**, 2785; (b) A. M. Kanazawa, A. Correa, J. N. Dennis, M. J. Luche and A. E. Green, *J. Org. Chem.*, 1993, **58**, 255.
  14. (a) B. K. Banik, M. S. Manhas and A. K. Bose, *Tetrahedron Lett.*, 1997, **38**, 5077; (b) B. K. Banik, M. Negi, M. S. Manhas and A. K. Bose, *Molecular Medicine REPORTS*, 2010, **3**, 317; (c) I. Banik and B. K. Banik, "Microwave-Induced Chemical Manipulation of  $\beta$ -Lactam", Springer, Berlin, Germany, 2012, **88**, 781; (d) B. K. Banik, "Beta Lactams: Novel Synthetic Pathways and Applications", Ed. Springer, 2017, 1; (e) B. K. Banik, Ed. Heterocyclic Scaffolds I. *Top. Heterocycl. Chem.*, Springer, 2010, **22**, 1; (f) B. K. Banik, *Top. Heterocycl. Chem.*, Springer, 2012, **30**, 1.
  15. (a) A. Das and B. K. Banik, *J. Indian Chem. Soc.*, 2020, **97**, 911; (b) A. Das and B. K. Banik, "Dipole Moment of Medicinally Active Compounds: A Sustainable Approach, In Green Approaches in Medicinal Chemistry for Sustainable Drug Design", Elsevier, UK, 2020, 921-964; (c) A. Das, A. K. Bose and B. K. Banik, *J. Indian Chem. Soc.*, 2020, **97**, 917; (d) A. Das and B. K. Banik, "Versatile thiosugars in medicinal chemistry, In Green Approaches in Medicinal Chemistry for Sustainable Drug Design", Elsevier, UK, 2020, 549-574; (e) A. Das, R. N. Yadav and B. K. Banik, Ascorbic Acid-mediated Reactions In Organic Synthesis, *Curr. Organocatal.*, 2020, 7; (f) A. Das and B. K. Banik, Dipole Moment, Encyclopedia (MDPI, Switzerland), 2020 (<https://encyclopedia.pub/1604>); (g) A. Das, A. K. Bose and B. K. Banik, Synthesis of  $\beta$ -Lactams, Encyclopedia (MDPI, Switzerland), 2020 (<https://encyclopedia.pub/1575>); (h) A. Das and B. K. Banik, Thiosugars of Biological Significance, Encyclopedia (MDPI, Switzerland), 2020 (<https://encyclopedia.pub/1552>); (i) A. Das and B. K. Banik, Ascorbic Acid-Induced Reactions, Encyclopedia (MDPI, Switzerland), 2020 (<https://encyclopedia.pub/2300>); (j) A. Das and B. K. Banik, Ascorbic Acid-Mediated Reactions, Encyclopedia (MDPI, Switzerland), 2020 (<https://encyclopedia.pub/2341>).